At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 454 enrolled
Drug / intervention
LCZ696 +5 moredrug
Likely dose
LCZ696 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension
In Brief
A Phase 2 clinical trial evaluating LCZ696, Olmesartan, and 4 other interventions for Hypertension. Completed, enrolled 454 participants across 47 sites in 12 countries.
Detailed Summary
The study examined the efficacy of LCZ696 in comparison to the ARB olmesartan on Central Aortic Systolic Blood Pressure (CASP) and other measures of central hemodynamics and arterial stiffness in elderly patients with an elevated systolic blood pressure (SBP) and widened pulse pressure (PP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesArgentina, Colombia, France, Germany, Greece, Italy, Japan, Russia, South Korea, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartDec 2012
Primary CompletionApr 2015
TodayJul 2026
First PostedSep 25, 2012
Enrollment StartDec 1, 2012
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.8 years ago
Interventions
LCZ696drug
200 mg tablet
Olmesartandrug
20 mg and 40 mg capsules
LCZ696 matching placebodrug
LCZ696 Matching Placebo tablet
Olmesartan matching placebodrug
Olmesartan matching placebo capsule
amlodipinedrug
amlodipine 2.5 mg or 5 mg tablets
hydrochlorothiazidedrug
hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets